In his 20 years in the US Army, Luis Alvarez got a close-up look at the damage improvised explosive devices (IEDs) could cause to the human body. The experience inspired him to pursue a PhD in tissue engineering at MIT – and, later, to found device start-up Theradaptive, Inc., which is developing a bone regeneration platform called OsteoAdapt SP. He now serves as the firm’s CEO.
The company, which holds three breakthrough device designations from the US Food and Drug Administration, recently got the agency’s blessing...
